Table 1 The laboratory and clinical features of the FMS and control groups
From: Determination of the increased risk of developing atrial fibrillation in fibromyalgia syndrome
FMS group n:70 | Control group n:70 | p | |
|---|---|---|---|
Age (years) | 38.0 ± 10.8 | 37.8 ± 9.9 | 0.516 |
SBP (mm Hg) | 123.4 ± 11.9 | 121.6 ± 9.6 | 0.739 |
DBP (mm Hg) | 79.8 ± 9.5 | 78.6 ± 8.9 | 0.577 |
MBP (mmHg) | 89.43 ± 8.60 | 88.86 ± 9.1 | 0.651 |
Hypertension (n (%)) | 5 (7.1) | 4 (5.7) | 0.844 |
BMI (kg/m2) | 26.6 ± 5.6 | 25.2 ± 4.7 | 0.284 |
Total cholesterol (mg/dL) | 179.8 ± 20.5 | 178.3 ± 19.8 | 0.794 |
Fasting glucose (mg/dL) | 87.8 ± 6.7 | 88.0 ± 6.6 | 0.936 |
TSH (uIU/mL) | 1.99 ± 0.38 | 1.87 ± 0.46 | 0.528 |
Serum creatinine, mg/dL | 1.04 ± 0.12 | 1.06 ± 0.14 | 0.654 |
Smokers (n (%)) | 11 (15.7) | 9 (12.8) | 0.698 |